Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

ical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. The study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). The design of the ongoing study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04). In March, Repligen exclusively licensed worldwide rights to a patent application from McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than two million adults in the U.S. have bipolar disorder.

HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. Preclinical studies have shown that HDAC inhibitors have the potential to arrest disease progression in Friedreich's ataxia, a novel approach to treating this debilitating disease. We have identified sever
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 Junto Health, ... startups share information and develop new technology solutions, today ... Policy Group (SPG), a leader in health care policy ... now engage in a collaborative innovation process while, at ... latest trends in public policy, health care finance and ...
(Date:7/27/2015)... Princeton Junction, NJ (PRWEB) , ... July 27, 2015 , ... ... Awards, which identify and celebrate the top 100 most innovative technologies and services of ... ® which was named in the Software/Services category. The winners will be announced at ...
(Date:7/25/2015)... ... 25, 2015 , ... Technology leader Anton Paar offers the ... the surface temperature of the measuring prism. This is required to achieve the ... documentation are key requirements. It is likely that no refractometer manufacturers on the ...
(Date:7/24/2015)... ... July 24, 2015 , ... VetStem Biopharma, proudly announces a new ... stem cell therapy training and clinical opportunities. , “We are very excited to be ... the San Diego area. Stem cell therapy is an established treatment for arthritic conditions ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2It’s T-Time for Refractometers: On-site Temperature Check Now Available 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... Choices, More Options to Global ... ... Feb. 11,/PRNewswire- FirstCall/ -- DuPont (NYSE: DD ) and Precision ... the market faster. Terms of the agreement were not,disclosed., The ...
... RICHMOND, Va., Feb. 11 A report released,today, commissioned ... savings of approximately $378 billion over the next 20 ... U.S., The econometric study by economist Dr. Robert ... Administration, found that "...generic,versions of the top 12 categories ...
... 11 On Monday, January 28, The ... the first,Volumetric Modulated Arc Therapy (VMAT)* treatment ... To facilitate the treatment, the hospital,used its ... generation,linear accelerator control system., (Logo: ...
Cached Biology Technology:DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 3Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 4Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 5Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... evolution works by reversing the process, reconstructing a 530-million-year-old ... genes that descended from the archaic gene. , "It ... evolution has occurred and is occurring, and thus makes ... and co-chairman of human genetics at the University of ...
... important new paper forthcoming in the June issue of ... University) argues against the widely held theory that the ... a large, replicating molecule such as RNA. Instead, ... a "stupendously improbable accident," presenting the more plausible idea ...
... of Warwick has found that sleep deprivation is associated ... obese for both children and adults. , Early results ... University of Warwick's Warwick Medical School were presented to ... the University of Warwick. , The research reviewed current ...
Cached Biology News:Scientists reverse evolution 2Scientists reverse evolution 3Scientists reverse evolution 4Scientists reverse evolution 5Sleep deprivation doubles risks of obesity in both children and adults 2
... Detergent Clean-up Micro Kit provides a fast and ... Triton X-100 and other detergents from small samples ... Norgens patented protein resin as an ion exchanger. ... g of either acidic or basic protein.A complete ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: